Abstract 1795P
Background
In the global ARCHES trial (NCT02677896), ENZA + ADT improved overall survival and radiographic progression-free survival (rPFS) vs PBO + ADT in pts with mHSPC. The China ARCHES trial evaluated the efficacy and safety of ENZA + ADT vs PBO + ADT in Chinese pts with mHSPC.
Methods
Chinese men with mHSPC (positive bone scan or CT scan) were randomized 2:1 to ENZA (160 mg/day) + ADT or PBO + ADT, stratified by disease volume and prior docetaxel therapy. Treatment continued until intolerability or confirmed radiographic progression. The primary endpoint was time to prostate-specific antigen (PSA) progression (TTPP; PSA progression defined as ≥25% increase and absolute increase of ≥2 ng/mL above the nadir, confirmed after ≥3 weeks), based on central laboratory test. Selected secondary endpoints included rPFS, time to castration resistance (TTCR), PSA undetectable (<0.2 ng/mL) rate in patients with detectable PSA at baseline, and safety. We report the results of a prespecified interim analysis (63 TTPP events accrued).
Results
At data cut-off (November 18, 2022), 180 pts (ENZA + ADT, n=120; PBO + ADT, n=60) had been randomized from 27 centers in China (median age, 68.5 years). Baseline characteristics were balanced between treatment arms. Median treatment duration with ENZA + ADT vs PBO + ADT was 25.66 vs 15.11 months. Based on 63 centrally confirmed PSA progressions (ENZA + ADT, 23; PBO + ADT, 40), ENZA + ADT significantly reduced the risk of PSA progression by 87% vs PBO + ADT (Table). rPFS, TTCR, and PSA undetectable rate were among the secondary endpoints improved with ENZA + ADT vs PBO + ADT. Safety outcomes in pts from China were consistent with those in the global ARCHES population. Table: 1795P
Endpoint | ENZA + ADT N=120 | PBO + ADT N=60 | Hazard ratioa (95% CI) | p value |
TTPPb (95% CI)c | NR (NR, NR) | 9.2 (6.54, 17.48) | 0.13 (0.076, 0.222) | <0.0001d |
rPFSb (95% CI)c | NR (28.25, NR) | 19.4 (13.63, NR) | 0.33 (0.196, 0.556) | <0.0001d,e |
TTCRb (95% CI)c | NR (31.18, NR) | 8.3 (6.41, 14.69) | 0.172 (0.107, 0.276) | <0.0001d,e |
PSA undetectable, % (95% CI)f | 76.3 (67.4, 83.8) | 22.8 (12.7, 35.8) | <0.0001e,g |
aCox proportional hazards modelh bMedian months: Kaplan-Meier method cBrookmeyer and Crowley method dLog-rank testh eNominal p value fClopper-Pearson method based on exact binomial distribution gCochran-Mantel-Haenszel score testh hStratified model/test CI=confidence interval; N=no. of randomized pts; NR=not reached.
Conclusions
Efficacy and safety results in China ARCHES were generally consistent with those in the global ARCHES trial.
Clinical trial identification
Editorial acknowledgement
Medical writing and editorial assistance were provided by Marietou Daou, MSc, and Jane Beck, MA, from Complete HealthVizion, IPG Health Medical Communications, funded by the study sponsors.
Legal entity responsible for the study
Astellas Pharma Inc.; Pfizer Inc.
Funding
This study was funded by Astellas Pharma Inc. and Pfizer Inc., the co-developers of enzalutamide.
Disclosure
F. Zhou, Z. Gongqian, H. Guo, Z. Hu, D. He, D. Zhang, Y. Li, H. Kadeerbai, Y. Liu, D. Ye: Non-Financial Interests, Institutional, Other, Study funding and support for Medical Writing/editing: Astellas; Non-Financial Interests, Institutional, Other, Medical writing/editing support: Complete HealthVizion. X. Zhang, Z. He: Non-Financial Interests, Institutional, Writing Engagement: Astellas Pharma Inc.
Resources from the same session
1239P - NHS-Galleri trial enrolment approaches and participant sociodemographic diversity
Presenter: Charles Swanton
Session: Poster session 14
1241P - Decoding the glycan code: Pioneering early detection of non-small cell lung cancer through glycoproteomics
Presenter: Kai He
Session: Poster session 14
1242P - Implementing functional precision oncology in real-world patients: Translating extensive in vitro data into personalized treatment combining genetics and functional assays
Presenter: Dörthe Schaffrin-Nabe
Session: Poster session 14
1243P - Ocular surface squamous neoplasia early diagnosis using an AI-empowered autofluorescence multispectral imaging technique
Presenter: Abbas HABIBALAHI
Session: Poster session 14
1244P - AI-based accurate PD-L1 IHC assessment in non-small cell lung cancer across multiple sites and scanners
Presenter: Ramona Erber
Session: Poster session 14
1245P - A lymph nodal staging assessment model for various histologic types of small intestinal tumors
Presenter: YOUSHENG LI
Session: Poster session 14
1246P - Detection of alternative lengthening of telomeres (ALT) across cancer types based on tumor-normal multigene panel sequencing
Presenter: Juan Blanco Heredia
Session: Poster session 14
1247P - A detection model for EGFR mutations in lung adenocarcinoma patients based on volatile organic compounds
Presenter: Yunpeng Yang
Session: Poster session 14
1248P - Development of a high performance and noninvasive diagnostic model using blood cell-free microRNAs for multi-cancer early detection
Presenter: Jason Zhang
Session: Poster session 14
1249P - Whole genome sequencing-based cancer diagnostics in routine clinical practice: An interim analysis of two years of real-world data
Presenter: Jeffrey van Putten
Session: Poster session 14